December 31, 2013 | December 31, 2012 | |||||||||||||||||
Gross | Accumulated Amortization | Net | Gross | Accumulated Amortization | Net | |||||||||||||
Intangible assets subject to amortization (Definite-lived) | ||||||||||||||||||
Customer lists | $ | 1,818 | $ | (393 | ) | $ | 1,425 | $ | 1,847 | $ | (330 | ) | $ | 1,517 | ||||
Patents | 519 | (160 | ) | 359 | 525 | (127 | ) | 398 | ||||||||||
Purchased and licensed technology | 1,999 | (1,129 | ) | 870 | 1,929 | (1,016 | ) | 913 | ||||||||||
Trademarks | 43 | (17 | ) | 26 | 57 | (29 | ) | 28 | ||||||||||
Other1 | 242 | (106 | ) | 136 | 206 | (98 | ) | 108 | ||||||||||
4,621 | (1,805 | ) | 2,816 | 4,564 | (1,600 | ) | 2,964 | |||||||||||
Intangible assets not subject to amortization (Indefinite-lived) | ||||||||||||||||||
In-process research and development | 43 | — | 43 | 62 | — | 62 | ||||||||||||
Microbial cell factories2 | 306 | — | 306 | 306 | — | 306 | ||||||||||||
Pioneer germplasm3 | 1,050 | — | 1,050 | 975 | — | 975 | ||||||||||||
Trademarks/tradenames | 881 | — | 881 | 819 | — | 819 | ||||||||||||
2,280 | — | 2,280 | 2,162 | — | 2,162 | |||||||||||||
Total | $ | 6,901 | $ | (1,805 | ) | $ | 5,096 | $ | 6,726 | $ | (1,600 | ) | $ | 5,126 | ||||
1. | Primarily consists of sales and grower networks, marketing and manufacturing alliances and noncompetition agreements. |
2. | Microbial cell factories, derived from natural microbes, are used to sustainably produce enzymes, peptides and chemicals using natural metabolic processes. The company recognized the microbial cell factories as an intangible asset upon the acquisition of Danisco. This intangible asset is expected to contribute to cash flows beyond the foreseeable future and there are no legal, regulatory, contractual, or other factors which limit its useful life. |
3. | Pioneer germplasm is the pool of genetic source material and body of knowledge gained from the development and delivery stage of plant breeding. The company recognized germplasm as an intangible asset upon the acquisition of Pioneer. This intangible asset is expected to contribute to cash flows beyond the foreseeable future and there are no legal, regulatory, contractual, or other factors which limit its useful life. |